Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

Italian Journal of Pediatrics

Volumn 43, Issue , 2017, Pages 1-18

  Pajno, Giovanni Battista ^a   Bernardini, Roberto ^b   Peroni, Diego ^c   Arasi, Stefania ^a,d   Martelli, Alberto ^e   Landi, Massimo ^f,g   Passalacqua, Giovanni ^h   Muraro, Antonella ⁱ   La Grutta, Stefania ^g   Fiocchi, Alessandro ^j   Indinnimeo, Luciana ^k   Caffarelli, Carlo ^l   Calamelli, Elisabetta ^m   Comberiati, Pasquale ⁿ   Duse, Marzia ^k  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAN GIUSEPPE HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e RHO HOSPITAL   (Italy)

^f Italian Federation of Pediatric Medicine   (Italy)

^g CNR   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^j BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF PARMA   (Italy)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

Allergen specific immunotherapy; Allergy; Asthma; Atopic dermatitis; Children; Food allergy; Sub lingual immunotherapy; Subcutaneous immunotherapy

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; EPINEPHRINE; IMMUNOGLOBULIN E; PLACEBO; PROBIOTIC AGENT; SALBUTAMOL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; ATOPIC DERMATITIS; BRONCHUS HYPERREACTIVITY; CHEST TIGHTNESS; CLINICAL PRACTICE; CONJUNCTIVITIS; CONSENSUS DEVELOPMENT; COUGHING; CROSS REACTION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG THERAPY; DYSPNEA; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD ALLERGY; FORCED EXPIRATORY VOLUME; HEARTBURN; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNOTHERAPY; ITALY; ORAL PRURITUS; PARESTHESIA; PEANUT ALLERGY; RADIOIMMUNOASSAY; REMISSION; REVIEW; RHINITIS; SEASONAL ALLERGIC CONJUNCTIVITIS; SENSITIZATION; STRIDOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SWELLING; THROAT IRRITATION; TONGUE EDEMA; UNCONSCIOUSNESS; URTICARIA; VOMITING; WHEEZING; CHILD; CLINICAL TRIAL (TOPIC); CONSENSUS; DESENSITIZATION; IMMUNOLOGY; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; PEDIATRICS; PRACTICE GUIDELINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHILD; CLINICAL TRIALS AS TOPIC; CONSENSUS; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; HUMANS; INJECTIONS, SUBCUTANEOUS; ITALY; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 85010868258     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/s13052-016-0315-y     Document Type: Review

References (135)

1. Pajno G, Bernardini R, Terracciano L, Duse M, Indinnimeo L, Calamelli E, et al. L’immunoterapia in età pediatrica. Rivista di Immunologia e Allergologia Pediatrica. 2014;4(Suppl 4):1-19.
2. Duse M, Minasi D, Pajno G, Pifferi M, Scala G, Terracciano L, et al. Immunoterapia allergene specifica: se, quando, come eseguirla. Revisione della letteratura ed Indicazioni. Documento della Commissione ITS della SIAIP. Rivista di Immunologia Allergologia Pediatrica. 2010;1(Suppl 2):1-29.
3. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556-68.
4. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
5. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127 Suppl 1:S1-S55.
6. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergen Immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immununol. 2013;131:1288-96.
7. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol. 2011;107:401-6.
8. Albin S, Nowak-Węgrzyn A. Potential treatments for food allergy. Immunol Allergy Clin N Am. 2015;35:77-100.
9. Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev. 2016;2:CD008774. doi:10.1002/14651858.CD008774.pub.
10. Li JT, Bernstein DI, Calderon MA, Casale TB, Cox L, Passalacqua G, et al. Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report. J Allergy Clin Immunol. 2016;137:369-76.
11. Passalacqua G, Canonica GW. Sublingual immunotherapy: focus on tablets. Ann Allergy Asthma Immunol. 2015;115:4-9.
12. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U, EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60:1459-70.
13. Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007, November, 008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003333.pdf.
14. Kaul S, May S, Lüttkopf D, Vieths S. Regulatory environment for allergen specific immunotherapy. Allergy. 2011;66:753-64.
15. Batard T. Quantification of major allergens and standardization of allergenic extract. Alergie (Czech). 1999;99:149-53.
16. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen- specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127:30-8.
17. Carnès J, Himly M, Gallego M, Iraola V, Robinson DS, Fernandez-Caldas E, et al. Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba. Clin Exp Allergy. 2009;39:426-34.
18. Pfaar O, van Twuijver E, Boot JD, Opstelten DJ, Klimek L, van Ree R, Diamant Z, Kuna P, Panzner P. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy. 2016;71:99-107.
19. Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005;138:197-202.
20. Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy Asthma Proc. 2016;37:50-6.
21. Sander I, Fleischer C, Meurer U, Brüning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy. 2009;64:1486-92.
22. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6:17.
23. Matricardi PM. Molecular profile clustering of IgE responses and potential implications for specific immunotherapy. Curr Opin Allergy Clin Immunol. 2013;13:438-45.
24. Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67:709-11.
25. Passalacqua G, Melioli G, Bonifazi F, Bonini S, Maggi E, Senna G, Triggiani M, Nettis E, Rossi RE, Vacca A, Canonica GW, Italian ISAC Study Group. The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy. 2013;68:1029-33.
26. Bousquet J, Lockey R, Malling HJ. Allergen Immunotherapy: therapeutic vaccines for allergic diseases. AWHO position paper. J Allergy Clin Immunol. 1998;102(4Pt1):558-62.
27. Passalacqua G, Canonica GW. Allergen Immunotherapy: History and Future Developments. Immunol Allergy Clin N Am. 2016;36:1-12.
28. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.
29. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
30. Miceli Sopo S, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma rhinitis and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child. 2004;89:620-4.
31. Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderón MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Ann Allergy Asthma Immunol. 2011;107:407-16.
32. Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64:669-77.
33. Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, Erekosima N. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155-67.
34. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one metaanalysis. J Investig Allergol Clin Immunol. 2005;15:9-16.
35. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Walter Canonica G. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133:599-609.
36. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141-8.
37. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160e3-6e3.
38. Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61:1177-83.
39. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167e7-73e7.
40. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific Immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol. 2009;102:22-8.
41. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol. 2009;9:168-76.
42. Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol. 2013;110:402-15.
43. Roeder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197-207.
44. Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, Rodriguez del Rio P, Tsoumani M, Gawlik R, Paraskevopoulos G, Ruëff F, Valovirta E, Papadopoulos NG, Calderón MA. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70:897-909.
45. Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Invest Allergol Clin Immunol. 1997;7:90-7.
46. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety of sublingual-swallow immunotherapy in children aged 3- to 7 years. Ann Allergy Asthma Immunol. 2005;95:254-8.
47. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60:133.
48. Pajno GB, Caminiti L, Passalacqua G. Changing the route of immunotherapy administration: an 18-year survey in pediatric patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2013;34:523-6.
49. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585-9.
50. Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol. 2011;127:44-5.
51. Arroabarren E, Tabar AI, Echechipía S, Cambra K, García BE, Alvarez-Puebla MJ. Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy. Pediatr Allergy Immunol. 2015;26:34-41.
52. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126:969-75.
53. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long term clinical efficacy in grass pollen-induced rhinoconconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131-8.
54. Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, Bahceciler NN, Barlan IB. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. J Investig Allergol Clin Immunol. 2015;25:334-42.
55. Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12.
56. Riccio AM, De Ferrari L, Chiappori A, Ledda S, Passalacqua G, Melioli G, Canonica GW. Molecular diagnosis and precision medicine in allergy management. Clin Chem Lab Med. 2016. [Epub ahead of print].
57. Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol. 2012;23:688-9.
58. Incorvaia C, Rapetti A, Scurati S, Puccinelli P, Cepecce M, Frati F. Importance of patient’s education in favouring compliance with sublingual immunotherapy. Allergy. 2010;65:1341-2.
59. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. The World Allergy Organization subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125:569-74.
60. Passalacqua G, Baena Cagnani CE, Bousquet J, Canonica GW, Casale TB, Cox L, et al. Grading local side effects of sublingual imunotherapy for respiratory allergy: speaking the same Language. J Allergy Clin Immunol. 2013;132:93-8.
61. Passalacqua G, Nowak-Wergzyn A, Canonica GW. Local side effects with sublingual and oral immunotherapy. J Allergy Clin Immunol Pract. 2016. In press.
62. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7(7):e41174.
63. Creticos PS, Bernstein DI, Casale TB, Lockey RF, Maloney J, Nolte H. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. J Allergy Clin Immunol Pract. 2016;4:1194-1204.e4. S2213-2198(16)30153-2.
64. Rank MA, Bernstein DI. Improving the safety of immunotherapy. J Allergy Clin Immunol Pract. 2014;2:131-5.
65. Spergel JM. Atopic March: link to upper airways. Curr Opin Allergy Clin Immunol. 2005;5:17-21.
66. Guerra S, Sherrill DL, Baldacci S, Carrozzi L, Pistelli F, Di Pede F, et al. Rhinitis is an independent factor for developing cough apart from colds among adults. Allergy. 2005;60:343-9.
67. Laynaert B, Neukirch C, Kony S, Guénégou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population based study. J Allergy Clin Immunol. 2004;113:86-93.
68. Shaabban R, Zureik M, Soussan D, Neukirch C, Heinrich C, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal-population based study. Lancet. 2008;372:1049-57.
69. Gough H, Grabenhenrich L, Reich A, Eckers N, Nitsche O, Schramm D, MAS study group, et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26:431-7.
70. Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis Patients and control subjects. J Allergy Clin Immunol. 1975;56:429-42.
71. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children: a 14-year study. Pediatrics. 1968;42:793-802.
72. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol. 2002;109:251-6.
73. Niggemann B, Jacbosen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow up on the PAT study: specific immunotherapy and long term prevention of asthma in children. Allergy. 2006;61:855-9.
74. Jacobsen L, Niggemann B, Dreborg S, Ferdousi A, Halken S, Host A. Specific immunotherapy has long term preventive effect on seasonal and periennal asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943-8.
75. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjuctivitis. J Allergy Clin Immunol. 2004;114:851-7.
76. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD, et al. Preventive effects of sublingual immunotherapy in childhhod: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101:206-11.
77. Pajno GB, Passalacqua G, Vita D, Caminiti L, Parmiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy : a randomized controlled trial. Allergy. 2004;59:883-7.
78. Promoting Tolerance to Common allergens in High Risk Children: Global Prevention of Asthma in Chidren (GPAC) Study. http://clinicaltrials.gov/ct2/show/NCT00346398?term=GPAC+Study&rank=1.
79. Grazax Asthma Prevention (GAP) Study. http://clinicaltrials.gov/ct2/show/NCT01061203?term=Grazax+Asthma+Prevention+%28GAP%29+Study&rank=1.
80. Mosges R, Klimek L. Today’s allergic rhinitis patients are different: new factors that may play a role. Allergy. 2007;62:969-75.
81. De Roches A, Paradis L, Menardo JL, Bourges S, Daurès S, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI Specific Immunotherapy prevents the onset of new sensitization in children. J Allergy Clin Immunol. 1997;99:450-3.
82. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitization in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six year follow-up study. Clin Exp Allergy. 2001;31:1392-7.
83. Purello D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S. Prevention of new sensitizations in monosenzitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy. 2001;31:1295-302.
84. Stelmach I, Sobocinska A, Maik P, Smeida K, Jerzynska J, Stelmach W. Comparison of the long term-term efficacy of 3- and 5-years house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol. 2012;109:274-8.
85. Tabar AI, Arroabarren E, Echechipìa S, Garcia BE, Martin S, Alvarez Buebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011;127:57-63.
86. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year perspective study. Clin Exp Allergy. 2003;33:206-10.
87. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ- standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in randomized trial. J Allergy Clin Immunol. 2012;129:717-25.
88. Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirica A. Comparison of the long term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. OLR J Otorhinolaryngol Relat Spec. 2008;70:144-50.
89. Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, et al. Prevalence of challenge-proven IgE-mediated food allergy using population based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol. 2011;127:668-76.
90. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126 Suppl 6:1-58.
91. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291-307.
92. Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69:1008-25.
93. Sicherer SH, Noone SA, Muñoz-Furlong A. The impact of childhood food allergy on quality of life. Ann Allergy Asthma Immunol. 2001;87:461-4.
94. Le T-M, Zijlstra WT, van Opstal EY, Knol MJ, L’Hoir MP, Knulst AC, Pasmans SGMA. Food avoidance in children with adverse food reactions: Influence of anxiety and clinical parameters. Pediatr Allergy Immunol. 2013;24:650-5.
95. Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010;65:933-45.
96. Indinnimeo L, Baldini L, De Vittori V, Zicari AM, De Castro G, Tancredi G, Lais G, Duse M. Duration of a cow-milk exclusion diet worsens parents’ perception of quality of life in children with food allergies. BMC Pediatr. 2013;13:203.
97. Arasi S, Otani IM, Klingbeil E, Bégin P, Kearney C, Dominguez TL, et al. Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies. Allergy, Asthma Clin Immunol. 2014;10:57.
98. Wood RA. Food allergen immunotherapy: Current status and prospects for the future. J Allergy Clin Immunol. 2016;137:973-82.
99. Burbank AJ, Sood P, Vickery BP, Wood RA. Oral Immunotherapy for Food Allergy. Immunol Allergy Clin N Am. 2016;36:55-69.
100. Fiocchi A, Dahdah L, Albarini M, Martelli A. Cow’s milk allergy in children and adults. Chem Immunol Allergy. 2015;101:114-23. doi:10.1159/000375415. Epub 2015 May 21.
101. Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in cow’s milk allergic patients: course and long-term outcome according to asthma status. Ann Allergy Asthma Immunol. 2015;114:240-4.
102. Yee CS, Rachid R. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. Curr Allergy Asthma Rep. 2016;16:25.
103. Romantsik O, Bruschettini M, Tosca MA, Zappettini S, Della Casa Alberighi O, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2014;11:CD010638.
104. Yeung JP, Kloda LA, Mc DeDevitt J, Ben-Shoshan M, Alizadehfar R. Oral Immnotherapy for milk allergy. Cochrane Datbase Syst Rev. 2012;11:CD009542.
105. Passalacqua G, Landi M, Pajno GB. Oral immunotherapy for cow’s milk allergy. Curr Opin Allergy Clin Immunol. 2012;12:271-7.
106. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol. 2014;133:318-23.
107. Nurmatov U, Venderbosh I, Devereux G, Simons FE, Sheikh A. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev. 2012;9:CD009014.
108. Passalacqua G, Nowak A, Canonica GW. Local side effects from sublingual and oral immunotherapy. J Allergy Clin Immunol Pract. 2016. In press.
109. Calderon MA, Demoly P, Gerth van Wijk R, Bousquet J, Sheikh A, Frew A, et al. EAACI: A European declaration in immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012;2:20.
110. Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1-8.
111. Capristo C, Romei I, Boner AL. Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens. Allergy. 2004;78:53-60.
112. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:542-6.
113. Bae JM, Chi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systemic review and meta-analysis of randomized controlled trial. J Allergy Clin Immunol. 2013;132:110-7.
114. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW, Passalacqua G. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164-70.
115. Novak K, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T, Sager A, Zuberbier T. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130:925-31.
116. Bonini S. Regulatory aspects of allergen-specific immunotherapy: Europe sets the scene for a global approach. World Allergy Organ J. 2012;5:120-3.
117. Guideline oh the Clinical Development of products for specific allergen immunotherapy for the treatment of allergic diseases (CHMP/EWP/18504/2006). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf.
118. EMA/PDCO Standard Paediatric Investigation Plan for Allergen Products for specific Allergen Immunotherapy. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500015814.pdf.
119. Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol. 2012;23:401.
120. Canonica GW, Bagnasco D, Ferrantino G, Ferrando M, Passalacqua G. Update on immunotherapy for the treatment of asthma. Curr Opin Pulm Med. 2016;22:18-24.
121. Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy Asthma Proc. 2016;37:50-6.
122. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation in allergen content in sublingual allergen immunotherapy with house dust mites. Allergy. 2015;70:1413-20.
123. Sastre J, Rodríguez F, Campo P, Laffond E, Marín A, Alonso MD. Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens. Allergy. 2015;70:598-600.
124. Sastre J. Molecular diagnosis and immunotherapy. Curr Opin Allergy Clin Immunol. 2013;13:646-50.
125. Caminiti L, Passalacqua G, Barberi S, Vita D, Barberio G, De Luca R, et al. A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. Allergy Asthma Proc. 2009;30(4):443-8.
126. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008;121(2):343-7.
127. Martorell A, De la Hoz B, Ibanez MD, Bone J, Terrados MS, Michavila A, et al. Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy. Clin Exp Allergy. 2011;41(9):1297-304.
128. Pajno G, Caminiti L, Ruggeri P, de Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Annals of Allergy Asthma & Immunology. 2010;105:376-81.
129. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122(6):1154-60.
130. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233-43.
131. Caminiti L, Pajno GB, Crisafulli G, Chiera F, Collura M, Panasci G, et al. Oral immunotherapy for egg allergy: A double blind placebo controlled study, with postdesensitizazion follow-up. Allergy: European Journal of Allergy and Clinical Immunology. 2015;70:99.
132. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebocontrolled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119-27.e1-7. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/460/CN-00841460/frame.html.
133. Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640-6.e1.
134. Tang MLK, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol. 2015;135(3):737-44.e8.
135. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654-60.